Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
4,034
Views
8
CrossRef citations to date
0
Altmetric
Coronavirus – Research Paper

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants

Sakshi Bajoriaa Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Kawaljit Kaura Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Ozan S. Kumrua Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
,
Greta Van Slykeb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAView further author information
,
Jennifer Doeringb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAView further author information
,
Hayley Novakb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAView further author information
,
Sergio A. Rodriguez Apontec Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA;d The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
,
Neil C. Dalvied The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;e Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USAView further author information
,
Christopher A. Naranjod The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
,
Ryan S. Johnstond The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
,
Judith Maxwell Silvermanf Bill & Melinda Gates Foundation, Seattle, WA, USAView further author information
,
Harry Kleanthousf Bill & Melinda Gates Foundation, Seattle, WA, USAView further author information
,
J. Christopher Loved The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;e Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USAView further author information
,
Nicholas J. Mantisb Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USAORCID Iconhttps://orcid.org/0000-0002-5083-8640View further author information
ORCID Icon,
Sangeeta B. Joshia Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USAView further author information
&
David B. Volkina Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1448-1998View further author information
ORCID Icon show all
Article: 2079346 | Received 25 Mar 2022, Accepted 16 May 2022, Published online: 06 Jun 2022

References

  • COVID-19 vaccine tracker and landscape [Internet]. World Health Organization; [accessed 2021 Aug 23]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
  • Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: what have we learned so far and what remains to be done? Health Policy (New York). 2021;125(5):1–17. doi:10.1016/j.healthpol.2021.03.013.
  • Director-General’s opening remarks at the media briefing on COVID-19 – 9 April 2021 [Internet]; [accessed 2021 Aug 28]. https://www.who.int/director-general/speeches/detail/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021.
  • Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine. 2021;39(3):457–59. doi:10.1016/j.vaccine.2020.12.017.
  • Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5(1):1–6. doi:10.1038/s41541-020-0159-8.
  • Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 2014;42(5):237–59. doi:10.1016/j.biologicals.2014.05.007.
  • Kavanagh MM, Gostin LO, Sunder M. Sharing technology and vaccine doses to address global vaccine inequity and end the COVID-19 pandemic. Jama. 2021;326(3):219–20. doi:10.1001/jama.2021.10823.
  • Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–48. doi:10.1126/science.abb2762.
  • Wang M-Y, Zhao R, Gao L-J, Gao X-F, Wang D-P, Cao J-M. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;10:724. doi:10.3389/fcimb.2020.587269.
  • Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–42.e21. doi:10.1016/j.cell.2020.09.037.
  • Law JLM, Logan M, Joyce MA, Landi A, Hockman D, Crawford K, Johnson J, LaChance G, Saffran HA, Shields J, et al. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. Vaccine. 2021;39(40):5769–79. doi:10.1016/j.vaccine.2021.08.081.
  • Chakraborti S, Prabakaran P, Xiao X, Dimitrov DS. The SARS coronavirus S Glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J. 2005;2(1):73. doi:10.1186/1743-422X-2-73.
  • Malladi SK, Singh R, Pandey S, Gayathri S, Kanjo K, Ahmed S, Khan MS, Kalita P, Girish N, Upadhyaya A, et al. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. J Biol Chem. 2021;296:100025. doi:10.1074/jbc.RA120.016284.
  • Dalvie NC, Biedermann AM, Rodriguez-Aponte SA, Naranjo CA, Rao HD, Rajurkar MP, Lothe RR, Shaligram US, Johnston RS, Crowell LE, et al. Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor-binding domain in engineered Komagataella phaffii. Biotechnol Bioeng. 2022;119(2):657–62. doi:10.1002/bit.27979.
  • Lee J, Liu Z, Chen W-H, Wei J, Kundu R, Adhikari R, Rivera JA, Gillespie PM, Strych U, Zhan B, et al. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021;105(10):4153–65. doi:10.1007/s00253-021-11281-3.
  • Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82. doi:10.1038/s41577-020-00480-0.
  • Kleanthous H, Silverman JM, Makar KW, Yoon I-K, Jackson N, Vaughn DW. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. NPJ Vaccines. 2021;6(1):1–10. doi:10.1038/s41541-021-00393-6.
  • Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 2000;30(Supplement_3):S266–270. doi:10.1086/313883.
  • Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–608. doi:10.1038/nm.3409.
  • Baylor NW, Egan W, Richman P. Aluminum salts in vaccines—us perspective. Vaccine. 2002;20:S18–23. doi:10.1016/S0264-410X(02)00166-4.
  • Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998;32(3):155–72. doi:10.1016/S0169-409X(98)00008-8.
  • Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82(5):497–505. doi:10.1111/j.0818-9641.2004.01286.x.
  • Awate S, Babiuk LAB, Mutwiri G. Mechanisms of Action of Adjuvants. Front Immunol [Internet]. 2013 [accessed 2021 Jan 18];4. 10.3389/fimmu.2013.00114
  • Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2012;3:406. doi:10.3389/fimmu.2012.00406.
  • Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377–89. doi:10.1016/j.vaccine.2014.06.065.
  • Shirota H, Klinman DM. CpG oligodeoxynucleotides as adjuvants for clinical use [Internet]. In: Immunopotentiators in modern vaccines. Elsevier Inc.; 2017 [accessed 2021 Nov 17]. p. 163–98. doi:10.1016/B978-0-12-804019-5.00009-8.
  • Campbell JD. Development of the CpG adjuvant 1018: a case study. Methods Mol Biol. 2017;1494:15–27.
  • HeplisavTM: a new hepatitis B vaccine. Future Virology [Internet]; [accessed 2021 Aug 22]. https://www.futuremedicine.com/doi/abs/10.2217/17460794.3.2.109.
  • Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 2004;199(1):201–16. doi:10.1111/j.0105-2896.2004.00148.x.
  • Mirotti L, Alberca Custódio RW, Gomes E, Rammauro F, de Araujo EF, Garcia Calich VL, Russo M. CpG-ODN shapes alum adjuvant activity signaling via MyD88 and IL-10. Front Immunol. 2017;8:47. doi:10.3389/fimmu.2017.00047.
  • Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M, Yokota S. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria–tetanus–pertussis vaccine. Vaccine. 2005;23(46–47):5450–56. doi:10.1016/j.vaccine.2004.09.041.
  • Texas children’s hospital and Baylor college of medicine covid-19 vaccine technology secures emergency use authorization in India. Texas Children’s Hospital [Internet]; [accessed 2022 Mar 4]. https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency
  • Thuluva S, Paradkar V, Turaga K, Gunneri S, Yerroju V, Mogulla R, Kyasani M, Manoharan SK, Medigeshi G, Singh J, et al. Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies Internet. Human Vacc Immunother. 2022 [accessed 2022 Mar 24]:1–11. https://www.medrxiv.org/content/10.1101/2022.03.08.22271822v2
  • Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–77. doi:10.1038/s41586-020-2599-8.
  • Pollet J, Strych U, Chen W-H, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, et al. Receptor-Binding domain recombinant protein RBD219-N1C1 on alum-CpG induces broad protection against SARS-CoV-2 variants of concern [Internet]. Mol Biol. 2021 [accessed 2021 Nov 16]. http://biorxiv.org/lookup/doi/10.1101/2021.07.06.451353
  • Dalvie NC, Rodriguez-Aponte SA, Hartwell BL, Tostanoski LH, Biedermann AM, Crowell LE, Kaur K, Kumru OS, Carter L, Yu J, et al. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. PNAS [Internet] 2021 [accessed 2021 Oct 10]; 118. https://www.pnas.org/content/118/38/e2106845118
  • Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–19. doi:10.1016/S1473-3099(21)00127-4.
  • Chen W-H, Pollet J, Strych U, Lee J, Liu Z, Kundu RT, Versteeg L, Villar MJ, Adhikari R, Wei J, et al. Yeast-Expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022;190:106003. doi:10.1016/j.pep.2021.106003.
  • Adimmune Corporation. A randomized, single center, open-label, dose-finding, phase i study to evaluate the safety and immunogenicity of pandemic virus vaccine, AdimrSC-2f (SARS-CoV-2), in healthy volunteers [Internet]. clinicaltrials.gov; 2021 [accessed 2021 Nov 16]. https://clinicaltrials.gov/ct2/show/NCT04522089.
  • United Biomedical Inc., Asia. A Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of UB-612 vaccine in healthy adult volunteers [Internet]. clinicaltrials.gov; 2021 [accessed 2021 Nov 16]. https://clinicaltrials.gov/ct2/show/NCT04545749
  • Sun S, He L, Zhao Z, Gu H, Fang X, Wang T, Yang X, Chen S, Deng Y, Li J, et al. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice. Cell Mol Immunol. 2021;18:1070–73.
  • Pan X, Shi J, Hu X, Wu Y, Zeng L, Yao Y, Shang W, Liu K, Gao G, Guo W, et al. RBD-Homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Cell Discov. 2021;7(1):1–15. doi:10.1038/s41421-021-00320-y.
  • An Y, Li S, Jin X, Han J, Xu K, Xu S, Han Y, Liu C, Zheng T, Liu M, et al. A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates [Internet]. Immunology. 2021 [accessed 2021 Nov 12]. http://biorxiv.org/lookup/doi/10.1101/2021.03.11.434928
  • Nanishi E, Borriello F, O’-Meara TR, McGrath ME, Saito Y, Haupt RE, Seo H-S, van HS, Cavazzoni CB, Brook B, et al. An aluminum hydroxide:cpg adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Sci Transl Med [Internet]. 2021 [accessed 2022 Jan 21]. https://www.science.org/doi/abs/10.1126/scitranslmed.abj5305
  • Pollet J, Chen W-H, Versteeg L, Keegan B, Zhan B, Wei J, Liu Z, Lee J, Kundu R, Adhikari R, et al. Sars‑cov-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Human Vacc Immunother. 2021;17(8):2356–66. doi:10.1080/21645515.2021.1901545.
  • Hamborg M, Foged C. Characterizing the association between antigens and adjuvants [Internet]. In: Foged C; Rades T; Perrie Y Hook S, editors. Subunit Vaccine Delivery. New York (NY): Springer; 2015 [accessed 2021 Nov 20]. p. 413–26. 10.1007/978-1-4939-1417-3_21
  • Sawant N, Kaur K, Holland DA, Hickey JM, Agarwal S, Brady JR, Dalvie NC, Tracey MK, Velez-Suberbie ML, Morris SA, et al. Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: case-study with Non-Replicating Rotavirus (NRRV) Vaccine antigens. J Pharm Sci. 2021;110(3):1042–53. doi:10.1016/j.xphs.2020.11.039.
  • McAdams D, Lakatos K, Estrada M, Chen D, Plikaytis B, Sitrin R, White JA. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant. J Immunol Methods. 2021;494:113056. doi:10.1016/j.jim.2021.113056.
  • Hotez PJ, Bottazzi ME. Whole inactivated virus and protein-based COVID-19 vaccines. Annu Rev Med. 2022;73(1):55–64. doi:10.1146/annurev-med-042420-113212.
  • Pollet J, Chen W-H, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:71–82. doi:10.1016/j.addr.2021.01.001.
  • Nanishi E, Dowling D, Levy O. Toward precision adjuvants: Optimizing science and safety. Curr Opin Pediatr. 2020;32(1):1. doi:10.1097/MOP.0000000000000868.
  • HogenEsch H, O’-Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018;3(1):1–11. doi:10.1038/s41541-018-0089-x.
  • Fox CB, Kramer RM, Barnes VL, Dowling QM, Vedvick TS. Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines. 2013;1(1):7–20. doi:10.1177/2051013613480144.
  • Xiao Y, Zeng Y, Alexander E, Mehta S, Joshi SB, Buchman GW, Volkin DB, Russell Middaugh C, Isaacs SN. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/cpg vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine. 2013;31(2):319–26. doi:10.1016/j.vaccine.2012.11.007.
  • Xiao Y, Zeng Y, Schante C, Joshi SB, Buchman GW, Volkin DB, Middaugh CR, Isaacs SN. Short-Term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus. Vaccine. 2020;38(38):6007–18. doi:10.1016/j.vaccine.2020.07.018.
  • Mullen GED, Aebig JA, Dobrescu G, Rausch K, Lambert L, Long CA, Miles AP, Saul A. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine. 2007;25(29):5343–47. doi:10.1016/j.vaccine.2007.05.007.
  • Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine. 2007;25(5):825–33. doi:10.1016/j.vaccine.2006.09.039.
  • Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–93. doi:10.1038/s41590-021-01122-w.
  • Beaudoin-Bussières G, Chen Y, Ullah I, Prévost J, Tolbert WD, Symmes K, Ding S, Benlarbi M, Gong SY, Tauzin A, et al. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Rep. 2022;38(7):110368. doi:10.1016/j.celrep.2022.110368.
  • Sedova ES, Scherbinin DN, Lysenko AA, Alekseeva SV, Artemova EA, Shmarov MM. Non-neutralizing antibodies directed at conservative influenza antigens. Acta Naturae. 2019;11(4):22–32. doi:10.32607/20758251-2019-11-4-22-32.
  • Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, et al. Comparative immunomodulatory evaluation of the receptor binding domain of the SARS-CoV-2 spike protein; a potential vaccine candidate which imparts potent humoral and Th1 Type immune response in a mouse model. Front Immunol. 2021;12:641447. doi:10.3389/fimmu.2021.641447.
  • Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem. 2005;280(14):13406–14. doi:10.1074/jbc.M500687200.
  • Iyer V, Hu L, Liyanage MR, Esfandiary R, Reinisch C, Meinke A, Maisonneuve J, Volkin DB, Joshi SB, Middaugh CR. Preformulation characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae. J Pharm Sci. 2012;101(9):3078–90. doi:10.1002/jps.23175.
  • Régnier M, Metz B, Tilstra W, Hendriksen C, Jiskoot W, Norde W, Kersten G. Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant. Vaccine. 2012;30(48):6783–88. doi:10.1016/j.vaccine.2012.09.020.
  • Agarwal S, Hickey JM, McAdams D, White JA, Sitrin R, Khandke L, Cryz S, Joshi SB, Volkin DB. Effect of aluminum adjuvant and preservatives on structural integrity and physicochemical stability profiles of three recombinant subunit rotavirus vaccine antigens. J Pharm Sci. 2020;109(1):476–87. doi:10.1016/j.xphs.2019.10.004.
  • Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev. 2000;24(1):45–66. doi:10.1111/j.1574-6976.2000.tb00532.x.
  • Dalvie NC, Tostanoski LH, Rodriguez-Aponte SA, Kaur K, Bajoria S, Kumru OS, Martinot AJ, Chandrashekar A, McMahan K, Mercado NB, et al. SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques. Sci Adv. 2022;8(11). doi:10.1126/sciadv.abl6015.
  • Fox C, Dutill T, Chesko J, Anderson R, Reed S, Vedvick T. Characterization of aluminum hydroxide gel and oil-in-water emulsion formulations containing CpG ODNs. BioPharm International. 2010;23:14–19.
  • Aebig JA, Mullen GED, Dobrescu G, Rausch K, Lambert L, Ajose-Popoola O, Long CA, Saul A, Miles AP. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods. 2007;323(2):139–46. doi:10.1016/j.jim.2007.04.003.
  • Mycroft-West C, Su D, Elli S, Li Y, Guimond S, Miller G, Turnbull J, Yates E, Guerrini M, Fernig D, et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor binding domain undergoes conformational change upon heparin binding [Internet]; 2020 [accessed 2022 Jan 21]. https://www.biorxiv.org/content/10.1101/2020.02.29.971093v2.
  • Neufurth M, Wang X, Tolba E, Lieberwirth I, Wang S, Schröder HC, Müller WEG. The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. Biochem Pharmacol. 2020;182:114215. doi:10.1016/j.bcp.2020.114215.
  • White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE, Maes EF, Oberste MS, et al. Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures. Biologicals. 2018;53:30–38. doi:10.1016/j.biologicals.2018.03.002.
  • Cai W, Ping L, Shen W, Liu J, Zhang M, Zhou J, Peng J, Wang M, Zhu Y, Ji G, et al. Potency of the Sabin inactivated poliovirus vaccine (sIPV) after exposure to freezing temperatures in cold chains. Human Vacc Immunother. 2020;16(8):1866–74. doi:10.1080/21645515.2019.1709352.
  • Murakami K, Fujii Y, Someya Y. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats. Vaccine. 2020;38(17):3295–99. doi:10.1016/j.vaccine.2020.03.027.
  • Nitahara Y, Nakagama Y, Kaku N, Candray K, Michimuko Y, Tshibangu-Kabamba E, Kaneko A, Yamamoto H, Mizobata Y, Kakeya H, et al. High-resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients. Microbiol Spectr. 2021;9(3):e0096521. doi:10.1128/Spectrum.00965-21.
  • Jiang M, Zhang G, Liu H, Ding P, Liu Y, Tian Y, Wang Y, Wang A. Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen. Front Immunol. 2021;12:707977. doi:10.3389/fimmu.2021.707977.
  • Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski E-S, Fera D. Structural analysis of neutralizing epitopes of the SARS-CoV-2 spike to guide therapy and vaccine design strategies. Viruses. 2021;13(1):134. doi:10.3390/v13010134.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.